190 related articles for article (PubMed ID: 15878792)
1. Substantial increases in idarubicin plasma concentration by liposome encapsulation mediates improved antitumor activity.
Dos Santos N; Waterhouse D; Masin D; Tardi PG; Karlsson G; Edwards K; Bally MB
J Control Release; 2005 Jun; 105(1-2):89-105. PubMed ID: 15878792
[TBL] [Abstract][Full Text] [Related]
2. Formulation and optimization of idarubicin thermosensitive liposomes provides ultrafast triggered release at mild hyperthermia and improves tumor response.
Lu T; Lokerse WJM; Seynhaeve ALB; Koning GA; Ten Hagen TLM
J Control Release; 2015 Dec; 220(Pt A):425-437. PubMed ID: 26541464
[TBL] [Abstract][Full Text] [Related]
3. Improved retention of idarubicin after intravenous injection obtained for cholesterol-free liposomes.
Dos Santos N; Mayer LD; Abraham SA; Gallagher RC; Cox KA; Tardi PG; Bally MB
Biochim Biophys Acta; 2002 Apr; 1561(2):188-201. PubMed ID: 11997119
[TBL] [Abstract][Full Text] [Related]
4. The encapsulation of idarubicin within liposomes using the novel EDTA ion gradient method ensures improved drug retention in vitro and in vivo.
Gubernator J; Chwastek G; Korycińska M; Stasiuk M; Grynkiewicz G; Lewrick F; Süss R; Kozubek A
J Control Release; 2010 Aug; 146(1):68-75. PubMed ID: 20510316
[TBL] [Abstract][Full Text] [Related]
5. Reduced uptake of liposomal idarubicin in the perfused rat heart.
Sermsappasuk P; Hrynyk R; Gubernator J; Weiss M
Anticancer Drugs; 2008 Aug; 19(7):729-32. PubMed ID: 18594215
[TBL] [Abstract][Full Text] [Related]
6. Drug release rate influences the pharmacokinetics, biodistribution, therapeutic activity, and toxicity of pegylated liposomal doxorubicin formulations in murine breast cancer.
Charrois GJ; Allen TM
Biochim Biophys Acta; 2004 May; 1663(1-2):167-77. PubMed ID: 15157619
[TBL] [Abstract][Full Text] [Related]
7. Oxidized phospholipid based pH sensitive micelles for delivery of anthracyclines to resistant leukemia cells in vitro.
Wang Y; Chen L; Ding Y; Yan W
Int J Pharm; 2012 Jan; 422(1-2):409-17. PubMed ID: 22037443
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic efficacy of a lipid-based prodrug of mitomycin C in pegylated liposomes: studies with human gastro-entero-pancreatic ectopic tumor models.
Gabizon A; Amitay Y; Tzemach D; Gorin J; Shmeeda H; Zalipsky S
J Control Release; 2012 Jun; 160(2):245-53. PubMed ID: 22134116
[TBL] [Abstract][Full Text] [Related]
9. A simple passive equilibration method for loading carboplatin into pre-formed liposomes incubated with ethanol as a temperature dependent permeability enhancer.
Wehbe M; Malhotra A; Anantha M; Roosendaal J; Leung AWY; Plackett D; Edwards K; Gilabert-Oriol R; Bally MB
J Control Release; 2017 Apr; 252():50-61. PubMed ID: 28286316
[TBL] [Abstract][Full Text] [Related]
10. Anti-CD19-targeted liposomal doxorubicin improves the therapeutic efficacy in murine B-cell lymphoma and ameliorates the toxicity of liposomes with varying drug release rates.
Allen TM; Mumbengegwi DR; Charrois GJ
Clin Cancer Res; 2005 May; 11(9):3567-73. PubMed ID: 15867261
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics and tissue distribution of idarubicin-loaded solid lipid nanoparticles after duodenal administration to rats.
Zara GP; Bargoni A; Cavalli R; Fundarò A; Vighetto D; Gasco MR
J Pharm Sci; 2002 May; 91(5):1324-33. PubMed ID: 11977108
[TBL] [Abstract][Full Text] [Related]
12. Dose dependency of pharmacokinetics and therapeutic efficacy of pegylated liposomal doxorubicin (DOXIL) in murine models.
Gabizon A; Tzemach D; Mak L; Bronstein M; Horowitz AT
J Drug Target; 2002 Nov; 10(7):539-48. PubMed ID: 12683721
[TBL] [Abstract][Full Text] [Related]
13. The effect of PEG coating on in vitro cytotoxicity and in vivo disposition of topotecan loaded liposomes in rats.
Dadashzadeh S; Vali AM; Rezaie M
Int J Pharm; 2008 Apr; 353(1-2):251-9. PubMed ID: 18191511
[TBL] [Abstract][Full Text] [Related]
14. An improved method of encapsulation of doxorubicin in liposomes: pharmacological, toxicological and therapeutic evaluation.
Gokhale PC; Radhakrishnan B; Husain SR; Abernethy DR; Sacher R; Dritschilo A; Rahman A
Br J Cancer; 1996 Jul; 74(1):43-8. PubMed ID: 8679456
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of liposomes and hyperthermia in a human tumor xenograft model: importance of triggered drug release.
Kong G; Anyarambhatla G; Petros WP; Braun RD; Colvin OM; Needham D; Dewhirst MW
Cancer Res; 2000 Dec; 60(24):6950-7. PubMed ID: 11156395
[TBL] [Abstract][Full Text] [Related]
16. Idarubicin: a brief overview on pharmacology and clinical use.
Borchmann P; Hübel K; Schnell R; Engert A
Int J Clin Pharmacol Ther; 1997 Feb; 35(2):80-3. PubMed ID: 9147715
[TBL] [Abstract][Full Text] [Related]
17. Liposomal topotecan formulation with a low polyethylene glycol grafting density: pharmacokinetics and antitumour activity.
Li C; Wang C; Yang H; Zhao X; Wei N; Cui J
J Pharm Pharmacol; 2012 Mar; 64(3):372-82. PubMed ID: 22309269
[TBL] [Abstract][Full Text] [Related]
18. A targeted liposome delivery system for combretastatin A4: formulation optimization through drug loading and in vitro release studies.
Nallamothu R; Wood GC; Kiani MF; Moore BM; Horton FP; Thoma LA
PDA J Pharm Sci Technol; 2006; 60(3):144-55. PubMed ID: 17089683
[TBL] [Abstract][Full Text] [Related]
19. Comparative plasma and tissue distribution of Sun Pharma's generic doxorubicin HCl liposome injection versus Caelyx
Burade V; Bhowmick S; Maiti K; Zalawadia R; Jain D; Rajamannar T
Cancer Chemother Pharmacol; 2017 May; 79(5):899-913. PubMed ID: 28349166
[TBL] [Abstract][Full Text] [Related]
20. Vascular targeting of doxorubicin using cationic liposomes.
Wu J; Lee A; Lu Y; Lee RJ
Int J Pharm; 2007 Jun; 337(1-2):329-35. PubMed ID: 17275230
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
